R. Michael Gendreau
2021
In 2021, R. Michael Gendreau earned a total compensation of $688.3K as Chief Medical Officer at Virios Therapeutics, a 2,194% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $113,750 |
|---|---|
| Option Awards | $228,412 |
| Salary | $325,000 |
| Other | $21,151 |
| Total | $688,313 |
Gendreau received $325K in salary, accounting for 47% of the total pay in 2021.
Gendreau also received $113.8K in non-equity incentive plan, $228.4K in option awards and $21.2K in other compensation.
Rankings
In 2021, R. Michael Gendreau's compensation ranked 9,951st out of 12,406 executives tracked by ExecPay. In other words, Gendreau earned more than 19.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,951 out of 12,406 | 20th |
Division Manufacturing | 4,399 out of 5,494 | 20th |
Major group Chemicals And Allied Products | 1,955 out of 2,369 | 18th |
Industry group Drugs | 1,737 out of 2,090 | 17th |
Industry Pharmaceutical Preparations | 1,291 out of 1,537 | 16th |
Source: SEC filing on April 26, 2022.
Gendreau's colleagues
We found three more compensation records of executives who worked with R. Michael Gendreau at Virios Therapeutics in 2021.
News
Virios Therapeutics CEO Greg Duncan's 2023 pay falls 39% to $567K
April 25, 2024
Virios Therapeutics CEO Greg Duncan's 2022 pay slips 15% to $937K
April 27, 2023
Virios Therapeutics CEO Greg Duncan's 2021 pay falls 69% to $1.1M
April 26, 2022
Virios Therapeutics CEO Greg Duncan receives $3.5M in 2020
April 28, 2021